Psilocybin Therapy, Explained by a Doctor

Dr. Tracy Kim Townsend, a physician, licensed psilocybin facilitator, and co-founder of the psychedelic medicine practice Meadow, gives a doctor's overview of psilocybin: what it is, how it may affect the brain, how it compares to standard antidepressants, and some of the clinical trial data behind the growing research interest in it. The video is educational only, and Townsend treats the findings as promising but still developing, not a settled cure.

What psilocybin is, and how it is regulated

Psilocybin is the psychoactive compound in more than 180 species of mushrooms that grow on every continent except Antarctica, Townsend says, with a long history of ceremonial and healing use. Unlike sedatives such as alcohol, psychedelics do not appear to blunt alertness or memory, and because they act outside the brain's dopamine reward pathway, they are not considered habit-forming; she cites a UK study that ranked psilocybin mushrooms as the least harmful substance assessed. She also notes the FDA's breakthrough therapy designations in 2018 and 2019 for depression and treatment-resistant depression, and says psilocybin has shown promise for anxiety, PTSD, addiction, and grief.

Serotonin, the default mode network, and antidepressants

Psilocybin is structurally similar to serotonin. In the body it converts to psilocin, acting mainly on the 5-HT2A serotonin receptor, heavily expressed in the default mode network, the circuitry Townsend calls the brain's "inner narrator," tied to rumination. Her theory: anxiety and depression involve an overactive default mode network, and quieting it lets other neural networks come online, often bringing a sense of expansion or relief. She contrasts this with antidepressants, which she says blunt emotional salience (why people often describe feeling flattened on them); psilocybin, in her framing, heightens it instead, letting people feel and reprocess difficult emotions. This is her clinical interpretation, not an established fact. Reported effects can include visual distortions, synesthesia, altered time sense, and mystical states.

Neuroplasticity and the research evidence

Townsend describes a window of heightened neuroplasticity lasting several weeks after dosing, best used for integration work with support, a theme covered in Psylopedia's integration guide. She cites a Johns Hopkins trial in which two sessions were associated with relief from depression lasting up to a year, with about 75 percent of participants responding and just over half in complete remission, plus fMRI research showing increased connectivity between the default mode network and executive brain regions. She calls these randomized, placebo-controlled trials, published in journals like the Lancet, the gold standard of evidence, while framing the research as ongoing. See Psylopedia's entry on psilocybe cubensis for more on the biology.

"Psilocybin doesn't just tweak brain chemistry. It alters the way that the brain is actually connected to itself," Townsend says.

Key takeaways

• ●Psilocybin is the active compound in over 180 mushroom species, with a long history of ceremonial and healing use.
• ●A UK study cited in the video ranked psilocybin mushrooms least harmful of those assessed; not considered habit-forming.
• ●The FDA granted breakthrough therapy status in 2018 and 2019 for depression and treatment-resistant depression.
• ●It acts mainly on the 5-HT2A serotonin receptor and appears to quiet the default mode network, tied to rumination.
• ●Unlike antidepressants, which Townsend says blunt emotional salience, psilocybin may heighten it, aiding emotional processing.
• ●A window of heightened neuroplasticity after dosing is described as key for integration work, ideally with support.
• ●A cited Johns Hopkins study found two sessions relieved depression for up to a year in about 75 percent of participants.
• ●The video is educational only; Townsend treats the research as promising but still developing.